NervGen Pharma Restates FY2024–FY2025 and Q2 2026 Financials Over Non-Cash Valuation Errors
NGEN sits 18% above its 52-week low of $1.58.
Summary
NervGen Pharma's audit committee determined that its FY2024, FY2025, and Q2 2026 financial statements should no longer be relied upon due to non-cash valuation errors in stock options and warrant liabilities. The restatement will not impact cash or liquidity.
Key Events · Corporate Governance and Compliance · NGEN
-
Non-Reliance on Prior Financials
Audit committee concluded FY2024, FY2025 audited financials and Q2 2026 unaudited interim financials should no longer be relied upon.
-
Non-Cash Valuation Errors Identified
Errors relate to stock option and derivative warrant liability valuations, reducing previously reported stock-based compensation expense and warrant liabilities.
-
No Cash or Liquidity Impact
Company states the restatement will not affect cash position, cash flow, or liquidity.
-
Restatement Plan
Company intends to amend Form 40-F for FY2025 and Form 6-K for Q2 2026; evaluation of final adjustments is ongoing.
Analysis · NGEN · Life Sciences
NervGen's audit committee has concluded that its audited financials for fiscal 2024 and 2025, plus its Q2 2026 interim financials, can no longer be relied upon. The errors are non-cash valuation mistakes in stock options and derivative warrant liabilities — meaning previously reported stock-based compensation expense and warrant liabilities were overstated. The company says the restatement will not affect cash, cash flow, or liquidity. This is a serious governance event: non-reliance on two years of audited financials and a recent quarter erodes investor confidence in the company's accounting controls, even though the corrections are non-cash and may actually improve reported earnings by reducing expenses.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NGEN was trading at $1.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $208.6M. The 52-week trading range was $1.58 to $6.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.